1. Data Extracted from the included studies:

Study name		Garcia‐Olmo 2009	Molendijk 2015	Melmed 2015	Panes 2016	Zhang 2018	Hawkey 2015	Zhou 2020
CCC of patients	Age	In ALL study 43.33, SD 9.9 I: mean 42.64, SD 10.93 P: 43.99, SD 8.97	Mean age: 38 Group 1: Mean: 40.4 (27‐54) Group 2: Mean: 40.8 (37‐47) Group 3: Mean: 33.4 (21‐48) Placebo: Mean: 37.3 (27‐49)	1 unit: mean 35.3 SD 14 4 units: mean 36.2 SD 11.6 Placebo: mean 36.5 SD7.3	I: mean 39.0 (13.1) P: mean 37.6 (13.1)	>18y‐70 years I:34.3 (21‐44) P: 32.7(20‐41)	I: Median: 34.1 IQR: (26.1‐41.2) P: Median: 30.6 IQR:(24.0‐37.6)	Range from; 12‐51 28.86 ± 10.13 I: 24.4 ± 5.0 C: 24.9 ± 5.4
	sex	In all study 24/25 M/F I: 10/14 P: 14/11	Male in 4 groups: 4/5 4/5 1/5 3/6 M/F: 12/9	1 unit:53.3% M/F:8/7 4 units:33.3 % 5/10 placebo:43.8% 7/9	I: 60/47 P: 56/49	I: 24/17 P: 26/15	Women: I: 13/23 P: 11/22	1 female 21 male (M/F) Intervention: 11/0 Control: 10/1
	Disease duration in years	Not mentioned	In years in 4 groups I: 7.6 (5‐11) II: 16.8 (5‐28) III: 13.2 (2‐23) Placebo: 6.8 (1‐20)	Mean I unit:18.5 yrs SD 13.8 4 units:10.4 yrs SD 10.7 placebo: 16.2 yrs SD9.4	I: 12.1 (10.0) P: 11.3 (8.9) years	I: 7 (2‐15) C: 8 (3‐14)	I: 14.9 y P: 11.2 y	Not mentioned
	Disease location	Rectovaginal fistula = 8/49 I= 4, P= 4 Suprasphincteric fistulous tract= 30/49 I= 14, P= 16	Perianal Group 1: L1= 1, L2 =3, L3=1 Group 2: L1= 1, L2=2,L3= 2 Group 3: L1=2,L2=1,L3=2 Placebo: L1=1,L2=2,L3=2, L3+L4=1		Perianal High inter‐sphincteric, trans‐sphincteric, extra‐sphincteric or supra‐sphincteric. (?)	I/C Ileal: 14/17 Colonic:18/14 Ileocolonic:9/10 Isolated upper:6/9		Intervention: Ileum (L1) 1 (9.1%) Colon (L2) 4 (36.4%) Ileocolon (L3) 6 (54.6%) Upper GI (L4) 0 (0.0%) Control: Ileum (L1): 1 (9.1%) Colon (L2): 3 (27.3%) Ileocolon (L3): 7 (63.6%) Upper GI (L4) 0 (0.0%)
Previous and concomitant medications		at least one complete course of antibiotics with a seton placement or conventional surgery (advancement flap or fistulectomy), at least one complete induction course of infliximab, unless anti‐TNF‐α treatment was contraindicated Concomitant: any except infliximab, tacrolimus, or cyclosporine	Mesalamine, steroids, anti TNF, immunosuppressives	Aminosalicylates‐corticosteroids‐immunomodulators‐biologics (at least 3m before study)	concomitant but refractory to immunomodulatory and anti‐TNF and antibiotics at randomisation	Steroids for the last 6 months and as background treatment Anticoagulation prior to treatment (2,500 IU of low‐molecular‐weight heparin )	I/P Prior drugs: Azathioprine/6MP:22/22 Methotrexate:19/18 Anti TNF:23/22 Other:10/9	During the study, all patients received aminosalicylic acid (Mesalazine) and probiotic treatment. One patient in the observation group and three patients in the control group received immunomodulator treatment. One patient in each group was given antibiotics.
Previous bowel surgeries		Yes (adv flap or fistulectomy) Previous fistula surgery: 39/49 I= 17, P= 22	None	None	None	I:12 P:9	I: 2/23 P: 2/22 Ileostomy: I: 4/23 P: 4/22	Not mentioned
Funding		This clinical trial has been sponsored by Cellerix S.L.	This work was supported by the DigestScience Foundation.	the study is funded by Celularity Incorporated	The study was funded by TiGenix	none mentioned	This study was sponsored by the European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party and the European Crohn and Colitis Organisation (ECCO).	This work was funded by Key Medical Science and Technology Development

Data here are not mentioned in the characteristics of the studies.